摘要
目的:观察培美曲塞(PEM)、多西紫杉醇(TAT)治疗晚期非小细胞肺癌(NSCLC)患者的临床效果。方法:选择晚期NSCLC40例随机分为两组,观察组采用PEM治疗;对照组采用TAT治疗,两组连用2个周期(21天/周期)。结果:两组总有效率、疾病控制率、中位无疾病进展生存期及1a生存率比较无显著性差异(P>0·05);观察组中性粒细胞减少低于对照组(P<0·05),两组非血液学毒性均为I-Ⅱ度,组间比较无差异性(P>0·05)。结论:对一线化疗失败或不能耐受的晚期NSCLC患者,PEM、TAT化疗的疗效相似,但以TAT不良反应低,值得临床应用。
Objective： Chapei U. S. music plug （ PEM）, docetaxel （TAT） in treatment of advanced non - small cell lung cancer （ NSCLC ） the clinical effect. Methods：Advanced NSCLC 40 patients were randondy divided into two groups to observe the group treated with PEM;the control group treated with TAT,two qd for 2 cycles （21 days/cycle）. Results：The total effective rate, disease control rate, median progression - free survival and survival 1a was no significant difference （P 〉 0. 05 ） ;neutrepenia observation group than the control group （ P 〈 0. 05 ） the two groups of non - hematologic toxicities were Ⅰ-Ⅱ degree, no difference between the two groups （P 〉 0. 05 ）. Conclusion：The failure or can not tolerate first -line chemotherapy in advanced NSCLC patients, PEM,TAT chemotherapy similar, but the low ad- verse reaction to TAT, is worthy of clinical application.
出处
《医学信息（中旬刊）》
2011年第5期1759-1760,共2页
Medical Information Operations Sciences Fascicule
